CAU
PHAT icon

Caxton Associates (UK)’s Phathom Pharmaceuticals PHAT Stock Holding History

Caxton Associates (UK)’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-181,968
Closed -$3.02M – 955
2025
Q4 		$3.02M Buy
181,968
+143,398
+372% +$2.05M 0.06% 122
2025
Q3 		$454K Buy
+38,570
New +$398K 0.01% 476

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Caxton Associates (UK)'s PHAT Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 181,968 shares — an estimated $3.02M sold.

Caxton Associates (UK) first reported a position in PHAT in Q3 2025 and held it in 2 quarters. The position peaked at $3.02M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 181,968 Phathom Pharmaceuticals shares in Q1 2026, an estimated $3.02M.
  • Caxton Associates (UK) first reported a position in Phathom Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Phathom Pharmaceuticals position peaked at $3.02M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.